Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor inhibit ferrous iron influx via divalent metal transporter 1 and iron regulatory protein 1 regulation in ventral mesencephalic neurons

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 12, 2014, Pages 2967-2975

  Zhang, Hao Yun ^a,b,c   Song, Ning ^a,b   Jiang, Hong ^a,b   Bi, Ming Xia ^a,b   Xie, Jun Xia ^a,b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Brain derived neurotrophic factor; Divalent metal transporter 1 with iron responsive element; Glial cell line derived neurotrophic factor; Iron regulatory protein 1; Parkinson's disease

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FERROUS ION; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IRON REGULATORY PROTEIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; OXIDOPAMINE; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; IRON TRANSPORT; MESENCEPHALON; MOLECULAR MECHANICS; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; UPREGULATION;

EID: 84907554716     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.09.010     Document Type: Article

References (59)

1. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
2. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998, 51:S2-S9.
3. Teismann P., Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res. 2004, 318:149-161.
4. Dexter D.T., Jenner P., Schapira A.H., Marsden C.D. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 1992, (32 Suppl.):S94-S100.
5. Rhodes S.L., Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol. Dis. 2008, 32:183-195.
6. Youdim M.B., Stephenson G., Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 2004, 1012:306-325.
7. Zecca L., Casella L., Albertini A., Bellei C., Zucca F.A., Engelen M., Zadlo A., Szewczyk G., Zareba M., Sarna T. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J. Neurochem. 2008, 106:1866-1875.
8. Mounsey R.B., Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int. J. Cell Biol. 2012, 2012:983245.
9. Halliwell B. Biochemistry of oxidative stress. Biochem. Soc. Trans. 2007, 35:1147-1150.
10. Altamura S., Muckenthaler M.U. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J. Alzheimers Dis. 2009, 16:879-895.
11. LaVoie M.J., Hastings T.G. Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J. Neurochem. 1999, 73:2546-2554.
12. Zheng W., Monnot A.D. Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol. Ther. 2012, 133:177-188.
13. Anderson C.P., Shen M., Eisenstein R.S., Leibold E.A. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim. Biophys. Acta 2012, 1823:1468-1483.
14. Zhang S., Wang J., Song N., Xie J., Jiang H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol. Aging 2009, 30:1466-1476.
15. Jiang H., Song N., Xu H., Zhang S., Wang J., Xie J. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res. 2010, 20:345-356.
16. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L.M., Nunez M.T., Garrick M.D., Raisman-Vozari R., Hirsch E.C. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18578-18583.
17. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 1999, 270:45-48.
18. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., Donnan G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 2000, 166:127-135.
19. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 1999, 10:557-561.
20. Kordower J.H., Bjorklund A. Trophic factor gene therapy for Parkinson's disease. Mov. Disord. 2013, 28:96-109.
21. Sullivan A.M., Toulouse A. Neurotrophic factors for the treatment of Parkinson's disease. Cytokine Growth Factor Rev. 2011, 22:157-165.
22. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci. 2005, 25:6251-6259.
23. Frim D.M., Uhler T.A., Galpern W.R., Beal M.F., Breakefield X.O., Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5104-5108.
24. Shults C.W., Kimber T., Altar C.A. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. Neuroreport 1995, 6:1109-1112.
25. Stahl K., Mylonakou M.N., Skare O., Amiry-Moghaddam M., Torp R. Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease. Brain Res. 2011, 1378:105-118.
26. Grandoso L., Ponce S., Manuel I., Arrue A., Ruiz-Ortega J.A., Ulibarri I., Orive G., Hernandez R.M., Rodriguez A., Rodriguez-Puertas R., Zumarraga M., Linazasoro G., Pedraz J.L., Ugedo L. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of Parkinsonized rats. Int. J. Pharm. 2007, 343:69-78.
27. Granholm A.C., Reyland M., Albeck D., Sanders L., Gerhardt G., Hoernig G., Shen L., Westphal H., Hoffer B. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J. Neurosci. 2000, 20:3182-3190.
28. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
29. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
30. Jakobsen B., Gramsbergen J.B., Moller Dall A., Rosenblad C., Zimmer J. Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF. Eur. J. Neurosci. 2005, 21:2939-2948.
31. Song N., Wang J., Jiang H., Xie J. Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. Free Radic. Biol. Med. 2010, 48:332-341.
32. Wang J., Song N., Jiang H., Xie J. Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons. Biochim. Biophys. Acta 2013, 1832:618-625.
33. Malgrange B., Lefebvre P., Van de Water T.R., Staecker H., Moonen G. Effects of neurotrophins on early auditory neurones in cell culture. Neuroreport 1996, 7:913-917.
34. Peng C., Aron L., Klein R., Li M., Wurst W., Prakash N., Le W. Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. J. Neurosci. 2011, 31:12802-12815.
35. Boyadjieva N.I., Sarkar D.K. Cyclic adenosine monophosphate and brain-derived neurotrophic factor decreased oxidative stress and apoptosis in developing hypothalamic neuronal cells: role of microglia. Alcohol. Clin. Exp. Res. 2013, 37:1370-1379.
36. Mullen L.M., Pak K.K., Chavez E., Kondo K., Brand Y., Ryan A.F. Ras/p38 and PI3K/Akt but not Mek/Erk signaling mediate BDNF-induced neurite formation on neonatal cochlear spiral ganglion explants. Brain Res. 2012, 1430:25-34.
37. 2-induced neuronal death. Neurobiol. Dis. 2005, 20:141-154.
38. Song N., Jiang H., Wang J., Xie J.X. Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J. Neurosci. Res. 2007, 85:3118-3126.
39. Lee P.L., Gelbart T., West C., Halloran C., Beutler E. The human Nramp2 gene: characterization of the gene structure, alternative splicing, promoter region and polymorphisms. Blood Cells Mol. Dis. 1998, 24:199-215.
40. Christova T., Templeton D.M. Effect of hypoxia on the binding and subcellular distribution of iron regulatory proteins. Mol. Cell. Biochem. 2007, 301:21-32.
41. Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 2000, 10:381-391.
42. Sariola H., Saarma M. Novel functions and signalling pathways for GDNF. J. Cell Sci. 2003, 116:3855-3862.
43. Cohen S., Levi-Montalcini R., Hamburger V. A nerve growth-stimulating factor isolated from sarcom as 37 and 180. Proc. Natl. Acad. Sci. U. S. A. 1954, 40:1014-1018.
44. Allen S.J., Watson J.J., Shoemark D.K., Barua N.U., Patel N.K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 2013, 138:155-175.
45. Wang J., Qian Z.M., Jiang H., Xie J., Ke Y. Treatment with nerve growth factor decreases expression of divalent metal transporter 1 and transferrin receptor in PC12 cells. Neurochem. Int. 2005, 47:514-517.
46. Mwanjewe J., Hui B.K., Coughlin M.D., Grover A.K. Treatment of PC12 cells with nerve growth factor increases iron uptake. Biochem. J. 2001, 357:881-886.
47. Schonfeld E., Yasharel I., Yavin E., Brand A. Docosahexaenoic acid enhances iron uptake by modulating iron transporters and accelerates apoptotic death in PC12 cells. Neurochem. Res. 2007, 32:1673-1684.
48. Weinreb O., Mandel S., Youdim M.B., Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic. Biol. Med. 2013, 62:52-64.
49. Hadzhieva M., Kirches E., Mawrin C. Iron metabolism and the role of iron in neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 2014, 40:240-257.
50. Berg D., Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov. Disord. 2006, 21:1299-1310.
51. Hirsch E.C. Iron transport in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S209-S211.
52. Xu H., Jiang H., Wang J., Xie J. Rg1 protects the MPP+-treated MES23.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology 2010, 58:488-494.
53. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117:285-297.
54. Wallander M.L., Leibold E.A., Eisenstein R.S. Molecular control of vertebrate iron homeostasis by iron regulatory proteins. Biochim. Biophys. Acta 2006, 1763:668-689.
55. Friedman W.J., Greene L.A. Neurotrophin signaling via Trks and p75. Exp. Cell Res. 1999, 253:131-142.
56. Numakawa T., Suzuki S., Kumamaru E., Adachi N., Richards M., Kunugi H. BDNF function and intracellular signaling in neurons. Histol. Histopathol. 2010, 25:237-258.
57. Chen Z., Chai Y., Cao L., Huang A., Cui R., Lu C., He C. Glial cell line-derived neurotrophic factor promotes survival and induces differentiation through the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathway respectively in PC12 cells. Neuroscience 2001, 104:593-598.
58. Peterson A.L., Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008, 5:270-280.
59. Wang Q., Lin Y., Zhang W., Liu M., Chen Y., Chen J., Luo W. Lead induces dysregulation of iron regulatory protein 1 via the extracellular signal-regulated kinase pathway in human vascular endothelial cells. Brain Res. 2012, 1455:19-27.